#Biond_Biologics
LightNews LightNews
newsen.bsky.social
Biond Biologics Accelerates Growth with Dr. Giovanni Selvaggi as Chief Medical Officer#Israel#Immunotherapy#Biond_Biologics#Misgav#Giovanni_Selvaggi
Biond Biologics Accelerates Growth with Dr. Giovanni Selvaggi as Chief Medical Officer
Biond Biologics announces the appointment of Dr. Giovanni Selvaggi as CMO, enhancing its oncology programs with his extensive experience in immunotherapies.
third-news.com
June 22, 2026 at 11:16 AM
newsen.bsky.social
Biond Biologics Partners with GIBF to Enhance Oncology Innovations in China#None#Biond_Biologics#Oncology_Therapies#GIBF#Misgav,_Guangzhou
Biond Biologics Partners with GIBF to Enhance Oncology Innovations in China
Biond Biologics has entered a strategic partnership with the GIBF to develop novel oncology therapies in China, securing an $8 million investment.
third-news.com
June 1, 2026 at 11:03 AM
newsen.bsky.social
Biond Biologics Launches Phase 2 Study for Innovative Cancer Treatment BND-22#Israel#cancer_therapy#Biond_Biologics#BND-22#Misgav
Biond Biologics Launches Phase 2 Study for Innovative Cancer Treatment BND-22
Biond Biologics has initiated a Phase 2 clinical trial for BND-22 combined with anti-PD-1 therapy, targeting advanced lung and cancer types.
third-news.com
October 8, 2025 at 12:28 PM
newsen.bsky.social
Biond Biologics Announces Strategic Reacquisition of BND-22 Rights Amid Promising Progress in Cancer Treatments#Israel#Biond_Biologics#BND-22#ILT2_receptor#Misgav
Biond Biologics Announces Strategic Reacquisition of BND-22 Rights Amid Promising Progress in Cancer Treatments
Biond Biologics regains full rights to BND-22 from Sanofi, advancing its promising immune checkpoint inhibitor targeting the ILT2 receptor to Phase 2 trials.
third-news.com
March 3, 2025 at 1:19 PM